Article Text

Download PDFPDF
Long-term outcomes of administration of intravitreal triamcinolone acetonide after posterior vitreous detachment during pars plana vitrectomy for proliferative diabetic retinopathy
  1. Mengyu Liao1,
  2. Yunli Huang1,
  3. Jiaxing Wang2,
  4. Xiangda Meng1,
  5. Yuanyuan Liu1,
  6. Jinguo Yu1,
  7. Hua Yan1
  1. 1Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China
  2. 2Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia, USA
  1. Correspondence to Professor Hua Yan, Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China; zyyyanhua{at}tmu.edu.cn

Abstract

Aim To evaluate the long-term outcomes of intravitreal triamcinolone acetonide (TA) administration after posterior vitreous detachment (PVD) during pars plana vitrectomy (PPV) for patients with proliferative diabetic retinopathy (PDR).

Methods A total of 189 eyes (152 patients) who underwent PPV for severe PDR were reviewed. Intravitreal injection of TA (IVTA) was administered during PPV in 118 eyes (PPV+IVTA group), and 71 eyes did not receive IVTA (PPV group). Immediately after PVD, when most of the vitreous and proliferative membranes were removed, 0.1 mL TA (40 mg/mL) was injected into the vitreous cavity in the PPV+IVTA group. All patients were followed-up for least 12 months. Visual outcomes and postoperative complications were recorded and compared between the two groups.

Results IVTA was helpful for proliferative membrane peeling and haemostasis during PPV. In the PPV+IVTA group, best-corrected visual acuity had significantly improved and the intraocular pressure was controlled well during the follow-up. The incidence of early recurrent vitreous haemorrhage after PPV was significantly lower in the PPV+IVTA group (1.7%) than in the PPV group (9.9%) (p=0.028).

Conclusion The administration of IVTA after PVD during PPV can effectively improve the final visual outcomes and prevent postoperative complications in patients with severe PDR.

  • retina
  • vitreous

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information.

Statistics from Altmetric.com

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information.

View Full Text

Footnotes

  • ML and YH contributed equally.

  • Contributors HY conceived and designed the study and is responsible for the overall content as guarantor. XM collected and reviewed the patient data. YL analysed and interpreted the data. ML and YH were the major contributors in writing the manuscript. JW and JY critically revised the manuscript.

  • Funding This study was supported by the National Natural Science Foundation of China (Grant Numbers 82020108007, 81830026) and the Beijing-Tianjin-Hebei Special Project (Grant Numbers 19JCZDJC64300(Z), 20JCZXJC00180).

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.